Insiders Hold Significant Stake in Greenwich LifeSciences, Inc.

Greenwich LifeSciences insiders own 53% of the company, indicating vested interests in its growth. The top 4 shareholders own 52% of the company. Past performance and ownership data can provide strong insights into a business's prospects. Institutional investors hold a significant portion of the company's stock, but insiders, particularly CEO Snehal Patel, have the most influence due to their 42% ownership stake.

Greenwich LifeSciences Inc. (GLSI) reported a quarterly adjusted loss of 30 cents per share for the period ended June 30, 2025, which was lower than the same quarter last year when the company reported an EPS of -20 cents. The lone analyst forecast for the quarter was for a loss of 24 cents per share. Reported revenue was zero, as expected by analysts [1].

The company's reported EPS for the quarter was a loss of 30 cents, resulting in a quarterly loss of $4.03 million. Despite the loss, GLSI shares have seen significant appreciation, rising by 33.2% this quarter and gaining 7.6% so far this year. The current average analyst rating on the shares is "buy," with a breakdown of recommendations showing 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." Wall Street's median 12-month price target for GLSI is $39.00, about 69% above its last closing price of $12.08 [1].

In a separate announcement, GLSI announced the expansion of its Phase III clinical trial, FLAMINGO-01, to Romania. The trial, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, has been formally approved by European regulators to add Romanian sites to the approximately 150 approved sites in Spain, France, Germany, Italy, Poland, and the US. The Romanian clinical sites will be led by Dr. Nicoleta Antone, who is serving as the national principal investigator in Romania for FLAMINGO-01 [2].

Greenwich LifeSciences insiders own 53% of the company, indicating a vested interest in its growth. The top 4 shareholders own 52% of the company, with institutional investors holding a significant portion of the stock. CEO Snehal Patel, who owns a 42% stake, has the most influence due to his significant ownership position [1].

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U7100:0-greenwich-lifesciences-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://www.nasdaq.com/press-release/greenwich-lifesciences-announces-expansion-flamingo-01-romania-2025-08-13